ADVERTORIAL: Taking control of LDL-C when statin therapy is not enough

25th May 2018

11033

TAGS
alirocumab
PCSK9 inhibitor
Praluent
Sanofi Aventis

dawnpowell

RELATED ARTICLES MORE FROM AUTHOR

Alirocumab receives EC approval in established atherosclerotic cardiovascular disease

The European Commission authorise use of evolocumab to reduce risk of myocardial infarction in patients with established cardiovascular disease

ACC 2018: Alirocumab reduces cardiovascular events in high-risk patients

LEAVE A REPLY Cancel reply

Please enter your comment!

Please enter your name here

You have entered an incorrect email address!

Please enter your email address here

Δ

Most read in past 7 days

SCAI publishes expert consensus statement on sex-specific considerations in myocardial revascularisation

4th February 2022

No sex difference seen in outcomes for transcatheter tricuspid valve intervention

5th January 2023

Boston Scientific gains US FDA clearance for AVVIGO+ multi-modality guidance system

27th September 2023

Features

Sham-controlled trials prompt renal denervation hypertension guideline update

18th August 2023

STS risk calculator uses power of big data to predict cardiac surgery risk

16th August 2023

“Not just inventing the next stent”: The future of medtech relies on patient empowerment

7th August 2023

Profiles

David Hildick-Smith

21st September 2023

Ruggero De Paulis

25th May 2023

Nieves Gonzalo

30th January 2023

Tweets by SpinalNewsInt

Write to us
Editorial: Will Date [email protected]
Advertising: Melanie Stevenson [email protected]

United Kingdom:

BIBA Medical, Europe
526 Fulham Road, Fulham, London, SW6 5NR
TEL: +44 (0)20 7736 8788
Email: [email protected]

United States:

BIBA Medical, North America
155 North Wacker Drive, Suite 4250, Chicago, IL 60606
TEL: +1 949 723 9309
Email: [email protected]

Terms and Conditions | Privacy Policy

Edit with Live CSS

Save
Write CSS OR LESS and hit save. CTRL + SPACE for auto-complete.